Chimie physique générale, Chimie thérapeutique Bertrand RIHN .................................. Biochimie ,
Chimie thérapeutique Chimie thérapeutique ,
Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique ,
Chimie organique Biophysique ,
Pharmacie galénique 3, Biochimie et Biologie, vol.1, issue.1 ,
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers, Br J Clin Pharmacol, vol.65, pp.5-18, 2008. ,
Osteonecrosis in HIV disease, AIDS, vol.17, issue.1, pp.1-9, 2003. ,
DOI : 10.1097/00002030-200301030-00003
Bone disease and HIV infection, Clin Infect Dis, vol.42, pp.108-122, 2006. ,
VIH/sida dans le monde??: de l?????pid??miologie au traitement universel, La Revue de M??decine Interne, vol.29, pp.269-73, 2008. ,
DOI : 10.1016/j.revmed.2008.10.002
The integrase interactor 1(IN1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription ,
HIV Infection and Bone Mineral Density in Middle-Aged Women, Clinical Infectious Diseases, vol.81, issue.8, pp.1014-1034, 2006. ,
DOI : 10.1210/jc.81.8.2948
URL : https://academic.oup.com/cid/article-pdf/42/7/1014/915442/42-7-1014.pdf
Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5??32, Journal of Biological Chemistry, vol.66, issue.49, pp.30603-30609, 1997. ,
DOI : 10.1093/nar/25.2.379
Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry, PLoS Pathogens, vol.13, issue.8, pp.10548-55, 2009. ,
DOI : 10.1371/journal.ppat.1000548.s004
Isentress-raltégravir. Fiche médicaments sortant de la réserve hospitalière, Actualités pharmaceutiques, vol.483, pp.55-61, 2009. ,
DOI : 10.1016/s0515-3700(09)70340-4
Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues, Antivir Ther, vol.13, pp.27-38, 2008. ,
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors, AIDS, vol.22, issue.3, pp.395-402, 2008. ,
DOI : 10.1097/QAD.0b013e3282f423dd
Stable frequency of HIV-1 transmitted drug resistance mutation over a decade (1996-2006) in France is likely explained by the increase of chronically treated patients in virological success, Antivir Ther, vol.12, p.49, 2007. ,
Identification of an Evolutionarily Conserved Domain in Human Lens Epithelium-derived Growth Factor/Transcriptional Co-activator p75 (LEDGF/p75) That Binds HIV-1 Integrase, Journal of Biological Chemistry, vol.73, issue.47, pp.48883-92, 2004. ,
DOI : 10.1093/bioinformatics/15.4.305
Maraviroc : r??sultats des ??tudes cliniques, M??decine et Maladies Infectieuses, vol.38, pp.17-23, 2008. ,
DOI : 10.1016/S0399-077X(08)70540-7
Structure and Function of HIV-1 Integrase, Current Topics in Medicinal Chemistry, vol.4, issue.9, pp.965-77, 2004. ,
DOI : 10.2174/1568026043388547
HIV-1 cell entry and advances in viral entry inhibitor therapy, Journal of Clinical Virology, vol.26, issue.2, pp.2228-2266, 2003. ,
DOI : 10.1016/S1386-6532(02)00111-7
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection, New England Journal of Medicine, vol.359, issue.4, pp.339-54, 2008. ,
DOI : 10.1056/NEJMoa0708978
impact du niveau d'expression du corécepteur CCR5 sur l'histoire naturelle de l'infection par VIH, Virologie, vol.10, issue.4, pp.279-86, 2006. ,
??pid??miologie de l???infection ?? VIH en France et en Europe, La Revue de M??decine Interne, vol.29, pp.266-68, 2008. ,
DOI : 10.1016/j.revmed.2008.10.004
HIV Integrase, a Brief Overview from Chemistry to Therapeutics, Journal of Biological Chemistry, vol.69, issue.26, pp.23213-23219, 2001. ,
DOI : 10.1016/0263-7855(87)80010-3
Les partenaires cellulaires de l'intégrase du VIH-1 : vers de nouvelles cibles thérapeutiques, Virologie, vol.11, pp.153-62, 2007. ,
Raltegravir, Drugs, vol.43, issue.5, pp.131-139, 2008. ,
DOI : 10.2165/00003495-200868010-00009
Les mécanismes de résistance à la transmission sexuelle du VIH-1. Médecines et maladies infectieuses, pp.517-541, 2005. ,
DOI : 10.1016/j.medmal.2005.09.003
Le maraviroc, un nouvel antirétroviral qui nécessite un test biologique, OptionBio, vol.412, 2009. ,
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity, J Virol, vol.69, pp.5908-911, 1995. ,
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction, The EMBO Journal, vol.17, issue.19, pp.5832-5875, 1998. ,
DOI : 10.1093/emboj/17.19.5832
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1, Nature Medicine, vol.19, issue.11, pp.1170-1172, 2005. ,
DOI : 10.1097/01.aids.0000183633.06580.8a
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial, The Lancet, vol.369, issue.9569, pp.1261-1270, 2007. ,
DOI : 10.1016/S0140-6736(07)60597-2
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection, New England Journal of Medicine, vol.350, issue.18, pp.1850-61, 2004. ,
DOI : 10.1056/NEJMoa031772
Antiretroviral drug resistance testing in adult HIV-1 infection: 2003 recommandations of an International AIDS-society-USA panel, Clin Infect Dis, vol.37, pp.1722-1725, 2003. ,
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences, Journal of Virology, vol.77, issue.24, pp.13376-88, 2003. ,
Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme, Drug Metabolism and Disposition, vol.35, issue.9, pp.1657-63, 2007. ,
DOI : 10.1124/dmd.107.016196
Les nouvelles mol??cules anti-VIH??: la place du ralt??gravir, Antibiotiques, vol.11, issue.1, pp.11-18, 2009. ,
DOI : 10.1016/j.antib.2008.12.001
Antiretroviral Activity of the Anti???CD4 Monoclonal Antibody TNX???355 in Patients Infected with HIV Type 1, The Journal of Infectious Diseases, vol.189, issue.2, pp.286-91, 2004. ,
DOI : 10.1086/380802
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science, vol.243, issue.4899, pp.1731-1765, 1989. ,
DOI : 10.1126/science.2467383
Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages ,
Th??rapeutiques antir??trovirales??: principes du traitement de l???infection par le VIH, La Presse M??dicale, vol.37, issue.6 ,
DOI : 10.1016/j.lpm.2007.10.016
Biology of CCR5 and Its Role in HIV Infection and Treatment, JAMA, vol.296, issue.7, pp.815-841, 2006. ,
DOI : 10.1001/jama.296.7.815
Les virus transmissibles par le sang, 1996. ,
Manifestations cliniques de l'infection par le virus de l'immunodéficience humaine. Editions Scientifiques et Médicales, 2002. ,
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, The Lancet, vol.374, issue.9692, pp.796-806, 2009. ,
DOI : 10.1016/S0140-6736(09)60918-1
Integration of HIV-1 DNA is regulated by interplay between viral Rev and cellular LEDGF/p75 proteins, Mol Med, vol.16, issue.12, pp.34-44, 2009. ,
Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The ???Mortalit?? 2000 and 2005??? Surveys (ANRS EN19 and Mortavic), JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.48, issue.5, pp.590-98, 2008. ,
DOI : 10.1097/QAI.0b013e31817efb54
Retroviral DNA Integration???Mechanism and Consequences, Adv Genet, vol.55, pp.147-181, 2005. ,
DOI : 10.1016/S0065-2660(05)55005-3
Impact of drug resistance mutations on virologic response to salvage therapy, AIDS, vol.13, issue.2, pp.17-21, 1999. ,
DOI : 10.1097/00002030-199902040-00001
Effect of DNA repair protein rad 18 on viral infection, PLoS Pathog, vol.2, pp.1-40, 2006. ,
Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients, AIDS, vol.21, issue.2, pp.187-92, 2007. ,
DOI : 10.1097/QAD.0b013e3280119e47
Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.46, issue.2, pp.125-158, 2007. ,
DOI : 10.1097/QAI.0b013e318157131c
Fondements de l'immunologie. Edition de Boeck Université. Traduction de la 11 ème édition anglaise du Roitt's essential immunology. 465 p Merck and Co. Mentions obligatoires complètes, 2008. ,
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science, vol.250, issue.4986, pp.1411-1424, 1990. ,
DOI : 10.1126/science.1701568
Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus???Infected Individuals, Clinical Infectious Diseases, vol.5, issue.4, pp.482-90, 2003. ,
DOI : 10.1210/jc.84.6.1932
The entry of entry inhibitors: A fusion of science and medicine, Proceedings of the National Academy of Sciences, vol.46, issue.5, pp.10598-602, 2003. ,
DOI : 10.1128/AAC.46.5.1336-1339.2002
Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region, Proceedings of the National Academy of Sciences, vol.379, issue.6568, pp.1120-1125, 1998. ,
DOI : 10.1038/379844a0
Structures et rôles de l'intégrase du VIH dans le cycle viral, Virologie, vol.11, pp.143-52, 2007. ,
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study), Journal of Antimicrobial Chemotherapy, vol.55, issue.2, pp.246-55, 2005. ,
DOI : 10.2165/00003088-200241010-00001
HIV-1 integrase strand transfer inhibitors: novel insights into their mechanism of action, Retrovirology, vol.2, pp.11-17, 2008. ,
Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection, Calcified Tissue International, vol.61, issue.1, pp.30-32, 1997. ,
DOI : 10.1007/s002239900288
Pharmacocin??tique clinique du maraviroc Clinical pharmacokinetic of maraviroc, M??decine et Maladies Infectieuses, vol.38, pp.12-18, 2008. ,
DOI : 10.1016/S0399-077X(08)70539-0
Integrase inhibitors to treat HIV/Aids, Nature Reviews Drug Discovery, vol.17, issue.3, pp.236-284, 2005. ,
DOI : 10.1038/9886
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy, AIDS, vol.18, issue.1, pp.81-89, 2004. ,
DOI : 10.1097/00002030-200401020-00010
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry, Virology, vol.361, issue.1 ,
DOI : 10.1016/j.virol.2006.11.004
Inhibiteurs du CCR5: développement clinique et perspectives thérapeutiques antirétrovirales, Virologie, vol.11, pp.120-129, 2007. ,
The prevalence of antiretroviral drug resistance in the United States, AIDS, vol.18, issue.10, pp.1393-401, 2004. ,
DOI : 10.1097/01.aids.0000131310.52526.c7
Diversit?? g??n??tique des VIH et ses cons??quences, Pathologie Biologie, vol.57, issue.2, pp.142-148, 2008. ,
DOI : 10.1016/j.patbio.2008.04.004
A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study, IAS) Conference on HIV Pathogenesis, Treatment and Prevention, 2007. ,
Reanalysis of the MERIT study with the enhanced Trofile assay, 48th International Conference on Antimicrobial Agents and Chemotherapy, 2008. ,
Tests de tropisme du VIH à l'heure de la mise à disposition du 1 er ,
Les inhibiteurs de CCR5 : une nouvelle classe d???antir??troviraux, M??decine et Maladies Infectieuses, vol.38, pp.1-6, 2008. ,
DOI : 10.1016/S0399-077X(08)70537-7
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125, p.350581 ,
Les résultats des essais cliniques concernant les inhibiteurs de l'intégrase du VIH, Virologie, vol.11, pp.183-92, 2007. ,
25 years of HIV-1 research ??? progress and perspectives, BMC Medicine, vol.3, issue.1, p.31, 2008. ,
DOI : 10.1186/1742-4690-3-87
SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV, Drug Metabolism and Disposition, vol.33, issue.4, pp.587-95, 2005. ,
DOI : 10.1124/dmd.104.002626
Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.566-75, 2007. ,
DOI : 10.1128/AAC.00853-06
A Three-dimensional Model of the Human Immunodeficiency Virus Type 1 Integration Complex, Journal of Computer-Aided Molecular Design, vol.76, issue.5, pp.301-318, 2005. ,
DOI : 10.1080/07391102.1998.10508285
Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses, Virology, vol.328, issue.1, pp.19-29, 2004. ,
DOI : 10.1016/j.virol.2004.07.021
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study, AIDS, vol.15, issue.6, pp.735-781, 2001. ,
DOI : 10.1097/00002030-200104130-00009
Prise en charge médicale des personnes infectées par le VIH, rapport 2008, recommandations du groupe d'experts. Edition Paris Flammarion médecine-sciences, 2008. ,
Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1, Nature Medicine, vol.22, issue.8, pp.920-926, 2001. ,
DOI : 10.1038/8811
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature, vol.140, issue.6685, pp.595-604, 1998. ,
DOI : 10.1007/BF00267823